Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β₂-agonist: post-hoc analyses of KRONOS.

ABSTRACT:

Background

In people with chronic obstructive pulmonary disease (COPD) on inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) therapy, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends stepping up to ICS/long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) in those with exacerbations or switching to LAMA/LABA in those with major symptoms. However, the effect of stepping up to ICS/LAMA/LABA versus switching to LAMA/LABA on exacerbation risk is unclear. This analysis evaluated the effect of escalating to ICS/LAMA/LABA versus switching to LAMA/LABA or staying on ICS/LABA on lung function and exacerbation rates in symptomatic individuals with COPD without a recent exacerbation history from KRONOS.

Methods

In KRONOS (NC

SUBMITTER: Singh D 

PROVIDER: S-EPMC12063277 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature